No products in the cart
How Cardiogen May Regulate Fibroblasts and Stimulate Tissue Repair
Cardiogen can work in tandem with another peptide with similar functions to boost the efficacy of some standard therapies, improving long-term outcomes while reducing side effects. Furthermore, preliminary Cardiogen studies in mouse models show that the peptide can increase tumor cell death.
The Medical Benefits and Functions of Cardiogen
Cardiogen Impacts on Cancer Cells
- A study on mice with M-1 sarcoma found that after Cardiogen administration, tumor cells had higher levels of Apoptosis or programed cell death. During this process, the body kills old cells or cells that have the potential to turn cancerous. The presence of hemorrhagic necrosis and activation of tumor cell apoptosis caused a dose-dependent inhibition of M-1 sarcoma growth after Cardiogen peptide injection. The measurements of proliferative activities show that the inhibition of tumor growth is not caused by the peptide’s cytostatic effect on the tumor. It is worth noting that the impact is dose-dependent, indicating that the biological product is absolute.
- Cardiogen induces apoptosis in tumor cells and may play a subtle role in tumor selection due to their increased and unusual vascular supply placing Cardiogen at the forefront of potential cancer adjuvants. Surprisingly, if Cardiogen peptide improves the efficacy of standard cancer treatments, it may be a critical addition to the cancer-fighting arsenal.
Cardiogen Peptide Impact on the Heart
- Cardiogen stimulates cardiomyocyte proliferation while inhibiting fibroblast growth and development in the heart, resulting in less scar formation and better long-term cardiac remodeling outcomes after heart failure. Furthermore, Cardiogen can reduce p53 protein expression, lowering apoptosis rates.
- Cardiogen can treat heart failure, hypertension, angina pectoris attacks, myocarditis, myocardial hypertrophy, coronary heart disease, and myocardiodystrophy in the elderly. It also improves stamina under adverse environmental conditions. Cardiogen treatment and prevention of cardiovascular diseases increase patients’ active longevity and lowers the risk of heart muscle pathologies.
The Function of Cardiogen Peptide in the Prostate
- Cardiogen, in conjunction with peptides with similar functions, has been shown in micropropagation studies to modulate the expression of signaling factors in prostate fibroblasts. Signaling factors are factors that promote the development and progression of prostate cancer. These levels are critical in establishing a favorable microenvironment within tumors, which contributes to the development and progression of prostate cancer. According to research, signaling factors are regulated in senescent and aging fibroblasts, which explains why prostate cancer is common in older men but rare in younger men.
- Furthermore, research shows that Cardiogen can stabilize signaling molecule levels to match or improve what is in young cultures. As a result, Cardiogen has the potential to be an essential adjuvant in the prevention and control of prostate cancer progression.
Other Benefits of Cardiogen Peptide
- Cardiogen boosts the body’s adaptability to the environment through immunity.
- The peptide improves the elasticity of reformed heart tissues qualitatively.
- Cardiogen peptide promotes heart muscle resistance to viral infection complications.
- It increases stamina in physical and mental overloads.
The Adverse Effects of Cardiogen Peptide
- According to research, Cardiogen has little to no adverse side effects. However, complications can be perceived under challenging people, pregnancy, and lactating mothers.
- Furthermore, Cardiogen peptide has both low and high oral and subcutaneous bioavailability in mouse models.
Cardiogen peptide is a peptide bioregulatory that can affect fibroblasts, cells in the body that regulate tissue repair and scar formation. Although the focus of Cardiogen has previously been on its impact on cardiovascular diseases, research shows that it can modulate fibroblast activities. Cardiogen, in collaboration with other peptides with similar functions, enhances the effects of some standard therapies, thereby improving long-term outcomes while mitigating adverse effects. Furthermore, preliminary Cardiogen studies in mice models show that the peptide can increase tumor cell apoptosis. Its medical benefits include symbiotic treatment of chronic heart failure, myocarditis, hypertrophy, angina myocardial hypertrophy, myocardiodystrophy, hypertension, heart attack, and other conditions.
Regardless, Cardiogen is a research peptide/chemical that is only for clinical and educational purposes, not for human consumption or use.
- Rello-Varona S, Herrero-Martín D, Lagares-Tena L, López-Alemany R, Mulet-Margalef N, Huertas-Martínez J, Garcia-Monclús S, García Del Muro X, Muñoz-Pinedo C, Tirado OM. The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy. Front Oncol. 2015 Apr 7;5:82. doi: 10.3389/fonc.2015.00082. PMID: 25905041; PMCID: PMC4387920.
- Levdik NV, Knyazkin IV. Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bull Exp Biol Med. 2009 Sep;148(3):433-6. English, Russian. doi: 10.1007/s10517-010-0730-9. PMID: 20396706.
- Di Donato M, Giovannelli P, Barone MV, Auricchio F, Castoria G, Migliaccio A. A Small Peptide Targeting the Ligand-Induced Androgen Receptor/Filamin a Interaction Inhibits the Invasive Phenotype of Prostate Cancer Cells. Cells. 2021 Dec 22;11(1):14. doi: 10.3390/cells11010014. PMID: 35011576; PMCID: PMC8750472.
- Roger L, Tomas F, Gire V. Mechanisms and Regulation of Cellular Senescence. Int J Mol Sci. 2021 Dec 6;22(23):13173. doi: 10.3390/ijms222313173. PMID: 34884978; PMCID: PMC8658264.
- Chalisova NI, Lesniak VV, Balykina NA, Urt’eva SA, Urt’eva TA, Sukhonos IuA, Zhekalov AN. [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats]. Adv Gerontol. 2009;22(3):409-13. Russian. PMID: 20210190.
Disclaimer: The products mentioned are not for human or animal consumption. All the information shared in this article is for educational purposes only.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.